证券代码：301267 证券简称：华厦眼科 公告编号：2025-031 华厦眼科医院集团股份有限公司 表决结果：同意7票；反对0票；弃权0票。 该议案已经公司董事会审计委员会审议通过。 上述具体内容详见公司同日发布于巨潮资讯网（www.cninfo.com.cn）的公 司《2025年第三季度报告》（公告编号：2025-032）。 2、审议通过《关于2025年中期利润分配方案的议案》 第三届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日上午以现场会议与通讯会议相结合的方式在公司会议室召开第三届董事会第 十一次会议，会议通知于 2025 年 10 月 22 日以电子邮件和即时通讯的方式送达。 本次会议应出席董事 7 名，实际出席董事 7 名（其中：委托出席董事 1 名，董 事苏庆灿先生因个人原因无法亲自出席会议，委托董事陈凤国先生出席会议并 代为行使表决权）；公司高管列席了本次会议。经全体参会董事一致推举，本 次会议由独立董事郑 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2025-033 华厦眼科医院集团股份有限公司 关于 2025 年中期利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第三届董事会第十一次会议，审议并通过了《关于 2025 年中期利润分配 方案的议案》。本次中期利润分配方案已取得公司 2024 年年度股东大会授权， 无需另行提交股东会审议。具体情况如下： 1、股东会授权情况 公司于 2025 年 5 月 20 日召开 2024 年年度股东大会，审议通过《关于提请 股东大会授权董事会决定 2025 年中期利润分配方案的议案》，授权董事会全权 处理 2025 年中期利润分配一切相关事宜，包括但不限于决定是否进行利润分配， 以及在符合有关法律、法规、规范性文件及《公司章程》规定的前提下，决定实 施利润分配的具体金额和时间等事宜。 2、董事会审议情况 公司于 2025 年 10 月 28 日召开第三届董事会第十一次会议，审议并通过了 《关于 20 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥1,132,883,729.40, representing a year-on-year increase of 0.13%[5] - The net profit attributable to shareholders for Q3 2025 was ¥151,682,862.05, a decrease of 2.37% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥145,557,749.72, showing a slight increase of 0.20% year-on-year[5] - Total operating revenue for the current period reached ¥3,271,797,099.40, an increase of 2.8% compared to ¥3,181,879,566.30 in the previous period[19] - Net profit for the current period was ¥456,066,099.99, compared to ¥442,334,462.70 in the previous period, indicating a growth of 3.1%[20] Assets and Liabilities - The total assets as of September 30, 2025, amounted to ¥8,163,130,801.02, reflecting a growth of 3.02% from the end of the previous year[5] - The company's total assets increased to ¥8,163,130,801.02 from ¥7,924,043,231.64, representing a growth of 3.0%[17] - Total liabilities rose to ¥1,954,785,761.96, up from ¥1,900,587,269.74, marking an increase of 2.8%[17] - The company's equity attributable to shareholders increased to ¥5,998,641,817.34 from ¥5,794,409,772.57, reflecting a growth of 3.5%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥698,110,689.68, an increase of 3.61%[5] - Net cash flow from operating activities was CNY 698,110,689.68, up from CNY 673,755,479.24 in the previous period[23] - Cash inflow from operating activities totaled CNY 3,331,087,546.30, slightly higher than CNY 3,314,706,537.36 last year[22] - Cash outflow from investing activities was CNY 9,327,290,666.34, compared to CNY 7,464,214,439.71 in the previous period, resulting in a net cash flow from investing activities of -CNY 2,866,790,736.89[23] - The company experienced a net cash outflow from financing activities of -CNY 391,334,969.96, an improvement from -CNY 439,006,413.53 in the previous period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,229[12] - The largest shareholder, Huaxia Medical Investment (Xiamen), holds 30.45% of shares, totaling 255,764,011 shares[12] - The second-largest shareholder, Su Qingcan, holds 30.41% of shares, totaling 255,405,989 shares[12] - The company has a total of 470,247,758 shares controlled by Su Qingcan and related parties, representing 63.00% of total shares[12] - The company has not disclosed any other shareholders with related party relationships or acting in concert[12] Expenses and Income - The company's financial expenses increased by 33.20% year-on-year, primarily due to the use of temporarily idle funds for financial products, resulting in reduced bank interest income[10] - The company reported a significant increase of 671.22% in trading financial assets, totaling ¥2,960,920,870.16, attributed to cash management strategies[10] - The asset disposal income increased by 521.00% year-on-year, mainly due to gains from the disposal of right-of-use assets[10] - The company experienced a 42.77% decrease in non-operating expenses, primarily due to reduced charitable donations[10] - Research and development expenses for the current period were ¥46,537,186.58, down from ¥53,903,578.99, a decrease of 13.7%[20] - The company reported an investment income of ¥31,396,054.12, compared to ¥45,033,384.18 in the previous period, showing a decline of 30.4%[20] Dividends - The company distributed a cash dividend of RMB 2.20 per 10 shares, totaling RMB 183,143,875.20 for the 2024 profit distribution[13] Cash and Cash Equivalents - The cash and cash equivalents decreased from RMB 3,487,699,580.40 to RMB 915,034,696.29[15] - The cash and cash equivalents increased to ¥323,526,661.10 from ¥240,471,990.33, a rise of 34.5%[17] - Cash and cash equivalents at the end of the period stood at CNY 909,526,296.29, down from CNY 1,084,478,851.40[23] Other Financial Metrics - The weighted average return on equity for the reporting period was 2.56%, a decrease of 0.15% compared to the same period last year[5] - Total comprehensive income for the period reached CNY 455,441,542.57, an increase from CNY 442,438,879.20 in the previous period[21] - Basic and diluted earnings per share increased to CNY 0.52 from CNY 0.50[21] - The financial report for the third quarter was not audited[25]

Core Insights - The first Zeiss Eye Health Management Center in China has officially opened in Jinan, marking a significant step in the collaboration between Huaxia Eye Hospital and Zeiss in building an eye health ecosystem [1][10] Group 1: Launch and Significance - The opening ceremony was attended by key leaders from both Huaxia Eye Hospital and Zeiss, highlighting the importance of this milestone in eye health management [3] - The center aims to reshape the public eye health management landscape by integrating Zeiss's advanced optical technology and precise diagnostic equipment with Huaxia Eye Hospital's clinical experience and data resources [9] Group 2: Service Model and Innovation - The center introduces a new integrated service model that encompasses "optometry-refraction-lens-fundus" for comprehensive eye health services [5] - It is designed to provide personalized, all-cycle eye health management for various age groups, emphasizing precision screening, scientific warning, systematic intervention, and dynamic follow-up [9] Group 3: Future Development and Collaboration - Leaders from Huaxia Eye Hospital expressed optimism about the center's future, viewing it as a proactive exploration and innovative practice in response to national eye health needs [13] - The collaboration with Zeiss extends beyond medical equipment to encompass full lifecycle eye health services, aiming to enhance the overall standardization and personalization of eye care [15] - Zeiss representatives acknowledged the significance of the center's establishment for their development and the deepening of their partnership with Huaxia Eye Hospital [17][18] Group 4: Vision and Mission - The center is positioned as a national demonstration center for promoting the concept of "full lifecycle eye health management," aiming to achieve high industry standards and broad recognition [20] - Huaxia Eye Hospital, as a large eye care chain, manages over 100 eye hospitals and clinics nationwide, focusing on balanced development in medical education and research [23] - The hospital is committed to providing quality eye care services to all patients, regardless of their socio-economic status, and aims to create long-term value for patients with eye diseases [23]

Core Insights - Tianjin Huaxia Eye Hospital actively participated in the "Light Journey" public welfare initiative, providing eye care services in remote areas like Tibet [1][5] - The hospital's commitment to comprehensive eye care is demonstrated through successful surgeries for patients with complex eye conditions [3][5] Group 1: Patient Care and Treatment - The hospital's cataract specialist, Dr. Wang Weijuan, conducted preliminary screenings in Tibet, leading to further treatment for patients in Tianjin [1][3] - The first patient, a monk suffering from night blindness and retinal pigment degeneration, underwent surgery by Professor Zhang Hong, an expert in cataract surgery, resulting in stable postoperative conditions [3] - The second patient, a nun with strabismus, received a comprehensive examination and corrective surgery, significantly improving her quality of life [3][5] Group 2: Institutional Commitment and Impact - The treatment journey of the two Tibetan patients reflects the hospital's dedication to the national eye health plan and its goal of providing high-quality medical resources to underserved areas [5] - The hospital aims to achieve full coverage of cataract surgery capabilities in rural regions, ensuring that all communities have access to advanced eye care [5] - The gratitude expressed by the Tibetan patients symbolizes the hospital's mission to serve every patient, regardless of their background, and to promote eye health [5]

Group 1 - The core viewpoint of the articles highlights Huaxia Eye Hospital's significant improvements in ESG ratings, reflecting its commitment to sustainable development and social responsibility [1][2][3] - Huaxia Eye Hospital achieved notable advancements in various ESG ratings, including an upgrade from BBB to A in Wind ESG rating and from B to A- in the Shandao Ronglv rating within three years [1] - The company has integrated party leadership into its ESG strategy, focusing on talent development and organizational strengthening, with 119 party members involved in training and development initiatives [1] Group 2 - In 2024, Huaxia Eye Hospital's "Qiao Aixin·Guangming Xing" initiative screened over 100,000 individuals and provided free surgeries for more than 5,000 impoverished eye disease patients [2] - The company has been actively involved in international aid, responding to the Belt and Road Initiative by conducting medical assistance in countries like Myanmar, Nepal, and Cambodia, with 760 consultations and 135 surgeries completed in Cambodia in 2024 [2] - Huaxia Eye Hospital's systematic approach to ESG has positioned it favorably in the capital market, potentially creating a development moat that combines social value with commercial resilience [2][3]

Core Insights - The article emphasizes the growing importance of ESG (Environmental, Social, and Governance) ratings as a key metric for assessing corporate health and long-term competitiveness, with companies like Huaxia Eye Hospital demonstrating exceptional ESG governance performance [1][2]. ESG Ratings and Performance - Huaxia Eye Hospital achieved remarkable ESG ratings, ranking in the top 24% globally in the S&P Global Corporate Sustainability Assessment, surpassing industry averages in environmental, social, and governance dimensions [1]. - The company has seen significant improvements in various domestic ESG rating systems, with Wind ESG rating rising from BBB to A, and other ratings also reflecting upward trends [1]. Policy Guidance and Framework - In 2024, the Ministry of Finance and other departments released guidelines for corporate sustainability disclosures, marking a new phase of standardization in China's ESG development [3]. - The Shenzhen Stock Exchange issued self-regulatory guidelines for sustainability reporting, requiring companies to publish their sustainability reports by April 30, 2026 [3]. Internal Mechanisms and Governance - Huaxia Eye Hospital has integrated ESG governance into its corporate strategy, establishing a dedicated committee under the board to oversee ESG strategy formulation and execution [3]. - The company has developed a comprehensive sustainable development policy framework, including environmental protection policies and supplier conduct guidelines, to support its ESG practices [4]. Employee Development and Social Responsibility - The company places a strong emphasis on employee development, with a focus on talent cultivation and a commitment to gender equality in the workplace [5][6]. - Huaxia Eye Hospital actively protects the rights of female employees, ensuring equal pay and providing necessary support during maternity [7]. Community Engagement and Philanthropy - The company engages in significant social responsibility initiatives, including free surgeries for impoverished patients and training local medical teams in underserved areas [8]. - Huaxia Eye Hospital has participated in international aid efforts, providing medical assistance in countries like Cambodia and Nepal, and has been recognized for its impactful community service [8][9]. Risk Management and Innovation - The company has established a robust risk management system covering supply chain, medical quality, and information security to ensure stable operations [9]. - Huaxia Eye Hospital is advancing its technological capabilities through the deployment of smart medical platforms and innovative models, enhancing its operational efficiency and service delivery [9].

Core Points - The establishment of the Department of Ophthalmology at Xiamen University Medical College aims to integrate ophthalmic talent and medical resources, focusing on cultivating high-level interdisciplinary ophthalmology professionals [1][6][10] - The department will leverage various high-level research platforms and collaborate with affiliated hospitals to enhance teaching and research capabilities [6][9] - The initiative is seen as a significant step in advancing regional ophthalmology and aims to position the department as a leading institution in both domestic and international ophthalmology [6][10] Summary by Sections Establishment and Leadership - The Department of Ophthalmology was officially established on October 11, coinciding with the 29th anniversary of Xiamen University Medical College [1][3] - The core management team includes Li Xiaoxin as the department head and Liu Zuguo as the executive deputy head [1][6] Vision and Goals - The department aims to promote integration between the university and its affiliated hospitals, enhancing the quality of ophthalmology education and research [2][6] - It seeks to become a benchmark for clinical department construction within the medical college, contributing to the improvement of clinical services and research capabilities in ophthalmology [2][6] Collaborative Framework - The department will collaborate with multiple high-level research platforms, including the Xiamen University Eye Research Institute and various key laboratories, to foster a comprehensive educational and research environment [6][9] - The affiliated hospitals, including the First Affiliated Hospital and others, will work together to share resources and enhance the department's development [9][10] Institutional Support - The establishment is supported by the Huaxia Eye Hospital Group, which has over 20 years of experience in the ophthalmology field and manages over 100 eye hospitals and clinics nationwide [10] - The group will provide teaching support and open clinical data and research platforms to facilitate the training of specialized ophthalmology professionals [10]

以下文章来源于网易清流工作室 ，作者梁耀丹 网易清流工作室 . 穿透迷雾，探寻真相。原创财经深度研究团队，信息来源均为公开的官方资料、媒体报道，以及普通人皆可查询的数据库文件等。 导语："左手捐钱、右手收钱"，或暗藏着眼科企业的赚钱密码——此前曾有媒体报道称，它们可能通过慈善行为赚取医保基金差价。 在做慈善这件事情上，眼科医院总是显得格外慷慨。 2022 年至 2024 年，国内连锁眼科医院市占率第一的爱尔眼科（ 300015.SZ ）对外捐赠 1.88 亿元、 3.87 亿元和 2.17 亿元。位居第二的华 厦眼科（ 301267.SZ ）捐赠金额同样不容小觑，分别捐赠了 6649.95 万元、 1.13 亿元和 7550.5 万元。 2022 年，爱尔眼科 甚至承诺， 未来十年捐资 200 亿元 用于公益事业。 这一豪言壮语背后，或隐藏着眼科企业别样的心思。 清流工作室查阅至少 14 家慈善机构年报后发现，以爱尔眼科、华厦眼科为代表的眼科巨头，通过给不同的慈善基金会捐赠资金，最终善款却通过 隐秘路径回流至企业自家账户。 这一 "左手捐钱、右手收钱"的运作模式，或暗藏着眼科企业的赚钱密码——此前曾有媒体报道 ...

Group 1 - The stock price of Huaxia Eye Hospital (301267.SZ) has declined by 2.60%, closing at 19.50 yuan, indicating that the stock is currently below its initial offering price [1] - Huaxia Eye Hospital was listed on the Shenzhen Stock Exchange's ChiNext board on November 7, 2022, with an initial offering price of 50.88 yuan per share [1] - The total funds raised from the initial public offering (IPO) amounted to 305.28 million yuan, with a net amount of 276.85 million yuan after deducting issuance costs [1] Group 2 - In the annual equity distribution announcement on July 4, 2023, Huaxia Eye Hospital declared a cash dividend of 2.8 yuan per 10 shares, totaling 15.68 million yuan [2] - The company also announced a capital increase by transferring 5 shares for every 10 shares held, increasing the total share capital from 56 million shares to 84 million shares [2] - The remaining undistributed profits will be carried forward for future distribution [2]